FDA reconsiders botanical drug pathway; Ionis nears Alexander disease approval

The FDA is revisiting its regulatory framework for botanical drugs, potentially easing approval paths for plant-based therapies. Separately, Ionis' first drug for Alexander disease is approaching approval, a rare pediatric CNS condition. The regulatory shift could lower barriers for a class of treatments previously hindered by complex chemistry requirements.